October 25, 2007

Jenex Receives Regulatory Approval in Australia

BURLINGTON, ON, - The Jenex Corporation (TSX Venture Exchange: JEN;

Frankfurt: JNX -at Yahoo Finance, use JEN.V) announced that it has been successful with the application for listing Therapik® as a medical device and it is now cleared to launch in Australia.

The distributor, Felton Grimwade & Bickford Pty Ltd (FGB) of Oakleigh South 3167, Australia will soon begin marketing Therapik® in Australia.

Jenex President Michael Jenkins commented: "We are pleased that the Australian regulatory authorities have awarded approval for the sale of Therapik® in so short a time. This additional approval will accelerate the commercialization phase of our business. We believe FGB's market knowledge and experience in Australia and New Zealand will help us meet and exceed our sales targets for these markets."

Mike McKelvie, CEO of FGB says: "We plan to launch in Australia in February. We look forward to distributing Therapik® to our many markets, as a device to eliminate the pain and discomfort of insect bites and stings. It is a product that would benefit every family."

About Felton Grimwade & Bickford Pty Ltd:  FGB is an independent Australian owned and operated natural products company.  It manufactures and markets a range of essential oils, O.T.C. pharmaceuticals, nutritional supplements, household products, personal care products, and medical devices in pharmacies and supermarkets throughout Australia, and in a growing number of export markets. (www.fgb.com.au)

About The Jenex Corporation:  Jenex has a non-invasive Medical Device that prevents cold sore outbreaks. The interceptCS™ Cold Sore Prevention System is approved in Canada and has received CE approval for European Union countries.  In addition to interceptCS, Jenex markets Therapik® for insect stings & bites. Therapik® immediately relieves the pain & itch caused by over 20,000 different insects. Therapik® is approved in Canada and the United States and Australia, as well as having CE Mark approval in the European Union countries.

Jenex's Thermal Therapy technology is patented in the U.S., Canada, Australia, & Europe.

Check www.interceptCS.com and www.JenexCorp.com for details.

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.

For further information

The Jenex Corporation, Michael A. Jenkins, (905) 632-3830, jenex@jenexcorp.com